Document Detail


Effects of allopurinol and deferoxamine on reperfusion injury of the brain in newborn piglets after neonatal hypoxia-ischemia.
MedLine Citation:
PMID:  12815112     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The hypothesis was tested that treatment with allopurinol, a xanthine oxidase inhibitor, or deferoxamine, a chelator of nonprotein-bound iron, preserved cerebral energy metabolism, attenuated development of edema, and improved histologic outcome in the newborn piglet at 24 h after hypoxia-ischemia. Thirty-two newborn piglets were subjected to 1 h of hypoxia-ischemia by occluding both carotid arteries and reducing the fraction of inspired oxygen; five newborn piglets served as sham-operated controls. The depth of hypoxia-ischemia was controlled by phosphorous magnetic resonance spectroscopy. Upon reperfusion and reoxygenation, piglets received vehicle (n= 12), allopurinol (30 mg/kg/d, n = 10), or deferoxamine (12.5 mg/kg/d, n = 10). The cerebral energy status was determined with phosphorous magnetic resonance spectroscopy. The presence of vasogenic edema was assessed by T2-weighted magnetic resonance imaging. Brain cell injury was assessed with caspase-3 activity, histology, and terminal deoxynucleotidyl transferase-mediated dUTP-biotin in situ nick end (TUNEL)-labeling. At 24 h after hypoxia-ischemia, the phosphocreatine/inorganic phosphate ratios were significantly decreased in vehicle-treated, but not in allopurinol- or deferoxamine-treated piglets. Water T2 values were significantly increased at 24 h after hypoxia-ischemia in cerebral cortex, thalamus, and striatum of vehicle-treated piglets, but not in allopurinol- and deferoxamine-treated piglets. No differences in caspase-3 activity, histologic outcome, or TUNEL-labeling were demonstrated between the three treatment groups. We suggest that allopurinol and deferoxamine may have an additional value in the treatment of perinatal hypoxia-ischemia with other neuroprotective agents or in combination with hypothermia.
Authors:
Cacha Peeters-Scholte; Kees Braun; Johanna Koster; Nicole Kops; Klas Blomgren; Giuseppe Buonocore; Sylvia van Buul-Offers; Henrik Hagberg; Klaas Nicolay; Frank van Bel; Floris Groenendaal
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2003-06-18
Journal Detail:
Title:  Pediatric research     Volume:  54     ISSN:  0031-3998     ISO Abbreviation:  Pediatr. Res.     Publication Date:  2003 Oct 
Date Detail:
Created Date:  2003-09-29     Completed Date:  2004-07-08     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0100714     Medline TA:  Pediatr Res     Country:  United States    
Other Details:
Languages:  eng     Pagination:  516-22     Citation Subset:  IM    
Affiliation:
Department of Neonatology, Image Sciences Institute, University Medical Center, 3584 EA Utrecht, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Allopurinol / metabolism,  pharmacology*
Animals
Animals, Newborn
Brain / drug effects*,  metabolism,  pathology
Caspase 3
Caspases / metabolism
Deferoxamine / metabolism,  pharmacology*
Enzyme Inhibitors / metabolism,  pharmacology*
Hypoxia-Ischemia, Brain / pathology*
In Situ Nick-End Labeling
Iron / metabolism
Iron Chelating Agents / metabolism,  pharmacology*
Magnetic Resonance Imaging
Reperfusion Injury / pathology*
Swine
Chemical
Reg. No./Substance:
0/Enzyme Inhibitors; 0/Iron Chelating Agents; 315-30-0/Allopurinol; 70-51-9/Deferoxamine; 7439-89-6/Iron; EC 3.4.22.-/Caspase 3; EC 3.4.22.-/Caspases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The relationship of von Willebrand factor binding to activated platelets from healthy neonates and a...
Next Document:  The role of parenteral lipids in supporting gluconeogenesis in very premature infants.